Operating profit rose 4.5% year-over-year to roughly $1.37 billion, reflecting efficient cost management and strong operational performance. DHL’s total revenue for the quarter was approximately $20.8 billion, up nearly 3% from about $20.2 billion in early 2024.

A key highlight was the launch of DHL Health Logistics, a new business unit focused on serving the pharmaceutical and healthcare sectors. DHL plans to invest around $2.2 billion into this initiative by 2030, aiming to expand its capabilities in areas such as biopharma, clinical trials, medical devices, and gene therapies. This move aligns with broader industry trends toward specialized logistics solutions in the growing healthcare market.

Looking forward, DHL reaffirmed its full-year outlook, expecting an operating result of at least $6.3 billion and free cash flow of about $3.2 billion, excluding mergers and acquisitions. The company emphasized that future performance could be influenced by trade and tariff policies, which could have both positive and negative effects on results.

With a focus on innovation and strategic growth, DHL is positioning itself to capitalize on the increasing demand for healthcare logistics and global supply chain resilience.